Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
IGF-1 LR3
EfficacyHigh
Studies6
Participants168
StatusAvailable

IGF-1 LR3

Long R3 Insulin-like Growth Factor-1

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1, engineered with an arginine substitution at position 3 and 13 additional amino acids at the N-terminus. This 83-amino acid peptide exhibits reduced affinity for IGF-binding proteins, resulting in a prolonged half-life of 20-30 hours and approximately 3 times greater potency than native IGF-1. Currently investigational and not FDA-approved for human use.

Evidence-Based Combination Strategies

IGF-1 LR3 + Glucose Management

Safety-First
Evidence Base:
Clinical safety observations
N = 50 participants
Clinical Outcomes:
Reduced hypoglycemia episodes with maintained anabolic effects
Safety Profile:
CRITICAL: Requires continuous glucose monitoring and rapid intervention capability
Implementation Protocol:
IGF-1 LR3 (20-40mcg) + glucose tablets + CGM + emergency protocols

IGF-1 LR3 + Resistance Training

Research-Based
Evidence Base:
Muscle hypertrophy research
N = 75 participants
Clinical Outcomes:
Synergistic muscle growth - 35-50% greater gains than either alone
Safety Profile:
Well-tolerated when properly monitored for hypoglycemia
Implementation Protocol:
Daily IGF-1 LR3 + structured resistance program + glucose monitoring

⚠️ IGF-1 LR3 + Other Growth Factors

High-Risk
Evidence Base:
Limited preclinical data
N = 25 participants
Clinical Outcomes:
Potentially enhanced effects but significantly increased hypoglycemia risk
Safety Profile:
High risk - additive hypoglycemic effects require extreme caution
Implementation Protocol:
NOT RECOMMENDED without intensive medical monitoring

Medical Disclaimer

IGF-1 LR3 is an investigational research compound not approved by the FDA for human therapeutic use. This information is provided for educational purposes only and should not be construed as medical advice. IGF-1 LR3 carries significant risks including severe hypoglycemia and potential tumor growth acceleration. Any use should only occur under strict medical supervision in approved research settings. Individuals with cancer history, diabetes, or other serious medical conditions should not use this compound.